[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 891
Citations 0
Correction
August 14, 2018

Undisclosed Conflict of Interest

JAMA. 2018;320(6):605. doi:10.1001/jama.2018.10664

In the Original Contribution entitled “Effect of Vitamin D Supplementation on Recurrent Wheezing in Black Infants Who Were Born Preterm: The D-Wheeze Randomized Clinical Trial,”1 published in the May 22/29, 2018, issue of JAMA, one of the authors, Kristie Ross, MD, MS, had an undisclosed conflict of interest. She recently discovered that Otsuka Pharma/Pharmavite donated the vitamin D and placebo being used in another trial on which she is a co-investigator, which is funded by the National Heart, Lung, and Blood Institute. Her conflict of interest disclosure should have read: “Dr Ross reported receiving grants and/or nonfinancial support from the National Institutes of Health, ODS, Boehringer Ingelheim, Teva, GlaxoSmithKline, Merck, Flamel, Jazz Pharmaceuticals, and Otsuka Pharma/Pharmavite.” The article has been corrected online.

References
1.
Hibbs  AM, Ross  K, Kerns  LA,  et al.  Effect of Vitamin D supplementation on recurrent wheezing in black infants who were born preterm: the D-Wheeze randomized clinical trial.  JAMA. 2018;319(20):2086-2094. doi:10.1001/jama.2018.5729PubMedGoogle ScholarCrossref
×